Suppr超能文献

利用细胞外容积心血管磁共振测量心肌纤维化以促进新型治疗方法的发展。

Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics.

作者信息

Schelbert Erik B, Sabbah Hani N, Butler Javed, Gheorghiade Mihai

机构信息

From the Department of Medicine, University of Pittsburgh School of Medicine, PA (E.B.S.); UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, PA (E.B.S.); Clinical and Translational Science Institute, University of Pittsburgh, PA (E.B.S.); Division of Cardiovascular Medicine, Department of Medicine, Henry Ford Health System, Detroit, MI (H.N.S.); Cardiology Division, Department of Medicine, Stony Brook University, NY (J.B.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (M.G.).

出版信息

Circ Cardiovasc Imaging. 2017 Jun;10(6). doi: 10.1161/CIRCIMAGING.116.005619.

Abstract

Quantifying myocardial fibrosis (MF) with myocardial extracellular volume measures acquired during cardiovascular magnetic resonance promises to transform clinical care by advancing pathophysiologic understanding and fostering novel therapeutics. Extracellular volume quantifies MF by measuring the extracellular compartment depicted by the myocardial uptake of contrast relative to plasma. MF is a key domain of dysfunctional but viable myocardium among others (eg, microvascular dysfunction and cardiomyocyte/mitochondrial dysfunction). Although anatomically distinct, these domains may functionally interact. MF represents pathological remodeling in the heart associated with cardiac dysfunction and adverse outcomes likely mediated by interactions with the microvasculature and the cardiomyocyte. Reversal of MF improves key measures of cardiac dysfunction, so reversal of MF represents a likely mechanism for improved outcomes. Instead of characterizing the myocardium as homogenous tissue and using important yet still generic descriptors, such as thickness (hypertrophy) and function (diastolic or systolic), which lack mechanistic specificity, paradigms of cardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on the extent of disease involving its various compartments. Specifying myocardial compartmental involvement may then implicate cellular/molecular disease pathways for treatment and targeted pharmaceutical development and above all highlight the role of the cardiac-specific pathology in heart failure among myriad other changes in the heart and beyond. The cardiology community now requires phase 2 and 3 clinical trials to examine strategies for the regression/prevention of MF and eventually biomarkers to identify MF without reliance on cardiovascular magnetic resonance. It seems likely that efficacious antifibrotic therapy will improve outcomes, but definitive data are needed.

摘要

通过心血管磁共振获取的心肌细胞外容积测量值来量化心肌纤维化(MF),有望通过深化病理生理理解和推动新型治疗方法的发展来改变临床护理。细胞外容积通过测量心肌对比剂摄取相对于血浆所描绘的细胞外间隙来量化MF。MF是功能失调但仍存活的心肌的一个关键领域(例如,微血管功能障碍和心肌细胞/线粒体功能障碍)。尽管这些领域在解剖学上是不同的,但它们可能在功能上相互作用。MF代表心脏中的病理重塑,与心脏功能障碍和不良结局相关,可能是由与微血管和心肌细胞的相互作用介导的。MF的逆转改善了心脏功能障碍的关键指标,因此MF的逆转是改善结局的一种可能机制。心脏病范式已不再将心肌描述为均质组织并使用重要但仍属通用的描述符,如厚度(肥厚)和功能(舒张期或收缩期),这些描述符缺乏机制特异性,而是根据疾病累及各个腔室的程度来概念化心肌疾病和患者易感性。明确心肌腔室受累情况可能会涉及细胞/分子疾病途径,以用于治疗和靶向药物开发,最重要的是突出心脏特异性病理在心力衰竭中的作用,而心脏及其他方面还有无数其他变化。心脏病学界现在需要2期和3期临床试验来研究MF消退/预防策略,并最终研究不依赖心血管磁共振来识别MF的生物标志物。有效的抗纤维化治疗似乎可能会改善结局,但需要确凿的数据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验